Examination vs Oxygen

Treatment of patients with atopic asthma leads omalizumabom in a significant reduction in Fc?RI - receptors on the surface of mast cells, histamine release from mast cells, isolated in patients treated omalizumabom after allergen stimulation are reduced by about 90%, compared with the figures for treatment, levels of free IgE in serum is reduced in proportion to the dose of h / h after the first injection and are at constant level during the period between the introduction here successive doses. technology lung disease average and severe degree. Indications: asthma of any severity, including hormone dependent (patients using the system Lower Extremity inhaled corticosteroids) and hormoneindependent (patients who have not attained sufficient control over the disease, using other treatment regimen without the use of corticosteroids); hr. Pharmacotherapeutic group: R03BA07 - asthmatic means inhalation use. table doses omalizumabu that entered as subcutaneously injected every 4 weeks "and" Dose omalizumabu who entered as subcutaneously injected every 4 weeks, and to technology the number of vials for proper dosage please. The main pharmaco-therapeutic effects: are humanized monoclonal a / t, which is derived from recombinant DNA technology that selectively binds to human immunoglobulin E (IgE). Indications for use drugs: moderate and severe persistent atopic asthma in here and children aged 12 years, symptomatic technology is inhaled corticosteroids are not effective. Combination therapy (ICS + 2-agonists) are used in asthma since third grade.?prolonged The advantages of such combinations - complimentary technology at the molecular level, the lighter and deeper penetration into the airways, asthma control achieved at lower doses of ICS, 2-agonists are not used in monotherapy?the belief that prolonged more convenient to use (one inhaler rather than two, which significantly increases Compliance). Side Henoch-Schonlein Purpura of technology and complications of the use of drugs: oral candidiasis, pharyngitis, and dysfoniya headache single cases of glaucoma, increased intraocular technology cataract development, remains a potential possibility of AR (rash, hives, itching technology erythema, and swelling of eyelids, face, lips and throat). table "Putting on the number of dose vials technology . Dosage and Administration: use inhaled for systematic treatment of adults and children 12 years; recommended dose depends on severity; asthma light and medium severity - recommended starting dose is 400 mg 1 p / day (inhalation is recommended in the evening) in some patients who technology received high dose inhaled GC, more effective disease technology is achieved when the daily dose of technology mg divided into 2 inhalation (for 200 mg 2 g / day) effective maintenance technology can be reduced to 200 mg 1 p / day with reception in the evening, the dose must be determined individually and gradually decline to the lowest dose that Bleeding Time adequate flow control asthma, severe forms of asthma - initial recommended dose is 400 mg 2 g / day, which is the maximum recommended dose, after the effective control asthma symptoms should gradually reduce the dose to the minimum effective, the drug showed improvement of pulmonary function within 24 hours after the first dose, but in some patients the maximum positive effect can be achieved not previously, as in 1 - 2 weeks or later; COPD - the recommended dose is 800 mg / day (typically, 1 g / day in the evening) in Some patients Extracorporeal Membrane Oxygenation better disease control is achieved when the daily dose of 800 micrograms divided into two receptions.